• Fri, May 5, 2023
Michael Ulz Maintained (BPMC) at Hold with Increased Target to $55 on, May 5th, 2023
Michael Ulz of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $50 to $55 on, May 5th, 2023.
Michael has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 3 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Benjamin Chaiken of "JMP Securities" Reiterated at Hold and Held Target at $114 on, Tuesday, February 28th, 2023
- Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $38 on, Friday, February 24th, 2023
- Peter Lawson of "Barclays" Maintained at Hold with Decreased Target to $44 on, Monday, January 23rd, 2023
This is the rating of the analyst that currently disagrees with Michael
- Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $85 on, Friday, February 17th, 2023